REFERENCES
- Food and Drug Administration. Oral Contraceptives and Thromboembolic Disorders, Current Drug Information. FDA, 1970; April 24
- Apelo R, Veloso I. Clinical experience with ethinyles- tradiol and D-norgestrel as an oral contraceptive. Fertil Steril 1975;26:283–8
- Nevinny Stickel J. German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethiny- lestradiol. Acta Obstet Gynecol Scand Suppl 1987;144:19–21
- Gestodene Study Group 322. The safety and contra- ceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 mg and ethinylestradiol 15 mg. Eur J Contracept Reprod Health Care 1999; 4(Suppl 2):9–15
- Kuhl H. Comparative pharmacology of newer progesto- gens. Drugs 1996;51:188–215
- Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and contraception: a review. Contraception 1995;52:137–41
- Ory HW. The noncontraceptive health benefits from oral contraceptives. Fam Plann Perspect 1982;14:182–4
- Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women’s perspective. Eur J Contracept Reprod Health Care 1996;1:275–84
- Kubba A, Guillebaud J, Anderson RA, et al. Contra- ception. Lancet 2000;356:1913–19
- Turgeon JL, McDonnell DP, Martin KA, et al. Hormone therapy: physiological complexity belies therapeutic simplicity Science 2004;304:1269–73
- Jewelewicz R. New developments in topical estrogen therapy. Fertil Steril 1997;67:1–12
- Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estrogen therapy. Drug Safety 1993;9:365–79
- Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561–82
- Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. Br Med J 1997;315:288
- Pierson RA, Archer DF, Moreau M, et al., for the Ortho EvraTM/EvraTM 008 Study Group. Ortho EvraTM/ EvraTM versus oral contraceptives: follicular develop- ment and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003;80:34–42
- Kuhl H. Comparative pharmacology of newer progesto- gens. Drugs 1996;51:188–215
- Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995;50:364–95
- Committee on Safety of Medicines/Medicines Control Agency. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Current Problems 1999;25:12
- Reuss ML, Kolton S, Tharakan T. Transvaginal ultra- sonography in gynecologic office practice: assessment in 663 premenopausal women. Am J Obstet Gynecol 1996; 175:1189–94
- Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583–90
- Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003;17:107–14